DK4045039T3 - Hæmning af human integrin-alfa4beta7 - Google Patents
Hæmning af human integrin-alfa4beta7Info
- Publication number
- DK4045039T3 DK4045039T3 DK20875989.4T DK20875989T DK4045039T3 DK 4045039 T3 DK4045039 T3 DK 4045039T3 DK 20875989 T DK20875989 T DK 20875989T DK 4045039 T3 DK4045039 T3 DK 4045039T3
- Authority
- DK
- Denmark
- Prior art keywords
- alfa4beta7
- inhibition
- human integrin
- integrin
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Radio Relay Systems (AREA)
- Air Conditioning Control Device (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916062P | 2019-10-16 | 2019-10-16 | |
| PCT/US2020/055986 WO2021076890A1 (en) | 2019-10-16 | 2020-10-16 | INHIBITING HUMAN INTEGRIN α4β7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4045039T3 true DK4045039T3 (da) | 2025-06-30 |
Family
ID=73198501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20875989.4T DK4045039T3 (da) | 2019-10-16 | 2020-10-16 | Hæmning af human integrin-alfa4beta7 |
Country Status (37)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112312910A (zh) | 2018-04-12 | 2021-02-02 | 莫菲克医疗股份有限公司 | 人整合素α4β7拮抗剂 |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| US11266643B2 (en) | 2019-05-15 | 2022-03-08 | Chemocentryx, Inc. | Triaryl compounds for treatment of PD-L1 diseases |
| CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| AU2020366435A1 (en) * | 2019-10-16 | 2022-04-21 | Morphic Therapeutic, Inc. | Inhibiting human integrin α4β7 |
| US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| US20250195485A1 (en) * | 2021-12-27 | 2025-06-19 | Xizang Haisco Pharmaceutical Co., Ltd. | Propionic acid derivative and medical use thereof |
| KR20250061759A (ko) | 2022-09-09 | 2025-05-08 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | 프로피온산 유도체 및 이의 의약에서의 응용 |
| WO2024138042A1 (en) | 2022-12-22 | 2024-06-27 | Xinthera, Inc. | Alpha4 beta7 integrin antagonists and uses thereof |
| TW202448866A (zh) * | 2023-02-21 | 2024-12-16 | 英商Ｃ4Ｘ探索有限公司 | 治療性化合物 |
| IL324720A (en) | 2023-05-26 | 2026-01-01 | Adarx Pharmaceuticals Inc | SOD1 modulators and methods of using them |
| WO2025026955A1 (en) * | 2023-07-28 | 2025-02-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| AU2024317579A1 (en) | 2023-07-28 | 2026-02-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof |
| WO2025176107A1 (zh) * | 2024-02-20 | 2025-08-28 | 西藏海思科制药有限公司 | 一种吡啶酮衍生物及其在医药上的应用 |
| CN118702712B (zh) * | 2024-07-04 | 2025-11-11 | 安徽普利药业有限公司 | 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法 |
| WO2026018017A1 (en) * | 2024-07-19 | 2026-01-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2026018016A1 (en) * | 2024-07-19 | 2026-01-22 | C4X Discovery Limited | Therapeutic compounds |
| CN119504796B (zh) * | 2024-11-20 | 2026-03-10 | 南通大学附属医院 | 一种具有抗肿瘤活性的化合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721366A (en) | 1993-03-31 | 1998-02-24 | G. D. Searle & Co | Platelet aggregation inhibitors |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| DE19622489A1 (de) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
| CA2268381A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| CA2268270A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Heterocyclic derivatives as factor xa inhibitors |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| ES2221227T3 (es) | 1997-11-24 | 2004-12-16 | MERCK & CO., INC. | Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular. |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| EP1091945A1 (en) | 1998-06-29 | 2001-04-18 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| AU4826900A (en) * | 1999-05-07 | 2000-11-21 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| ATE364592T1 (de) | 1999-09-24 | 2007-07-15 | Genentech Inc | Tyrosinderivate |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| PL365729A1 (en) * | 2000-08-30 | 2005-01-10 | Pharmacia Corporation | Gem-substituted alpha v beta 3 integrin antagonists |
| DE10111876A1 (de) | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
| DE10154280A1 (de) | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
| SI1485127T1 (sl) | 2002-02-25 | 2011-09-30 | Elan Pharm Inc | Dajanje aktivne snovi za zdravljenje vnetja |
| WO2006026759A2 (en) | 2004-09-03 | 2006-03-09 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| ES2387317T3 (es) | 2005-03-03 | 2012-09-20 | Seedlings Life Science Ventures, Llc. | Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| DE602006019731D1 (de) | 2005-06-09 | 2011-03-03 | Ucb Pharma Sa | 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| WO2010091411A1 (en) | 2009-02-09 | 2010-08-12 | Glaxosmithkline Llc | Piperidinyl cyclic amido antiviral agents |
| KR20130137688A (ko) | 2011-03-31 | 2013-12-17 | 제넨테크, 인크. | 베타7 인테그린 길항제를 투여하는 방법 |
| KR101850591B1 (ko) | 2012-10-05 | 2018-04-19 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
| MA39804A (fr) | 2014-03-27 | 2017-02-01 | Hoffmann La Roche | Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin |
| WO2016011940A1 (zh) | 2014-07-25 | 2016-01-28 | 江苏恒瑞医药股份有限公司 | 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用 |
| EP3581585A1 (en) * | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| EP3978530A1 (en) | 2015-02-26 | 2022-04-06 | F. Hoffmann-La Roche AG | Integrin beta7 antagonists and methods of treating crohn's disease |
| SG11201907820SA (en) * | 2017-02-28 | 2019-09-27 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| CN112312910A (zh) | 2018-04-12 | 2021-02-02 | 莫菲克医疗股份有限公司 | 人整合素α4β7拮抗剂 |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| US11179383B2 (en) * | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| AU2020366435A1 (en) | 2019-10-16 | 2022-04-21 | Morphic Therapeutic, Inc. | Inhibiting human integrin α4β7 |
-
2020
- 2020-10-16 AU AU2020366435A patent/AU2020366435A1/en active Pending
- 2020-10-16 HR HRP20250749TT patent/HRP20250749T1/hr unknown
- 2020-10-16 CN CN202411308053.XA patent/CN119192137A/zh active Pending
- 2020-10-16 MD MDE20220933T patent/MD4045039T2/ro unknown
- 2020-10-16 PE PE2022000633A patent/PE20221829A1/es unknown
- 2020-10-16 WO PCT/US2020/055986 patent/WO2021076890A1/en not_active Ceased
- 2020-10-16 SI SI202030622T patent/SI4045039T1/sl unknown
- 2020-10-16 MA MA57399A patent/MA57399B1/fr unknown
- 2020-10-16 US US17/072,797 patent/US11104661B1/en active Active
- 2020-10-16 MX MX2022004406A patent/MX2022004406A/es unknown
- 2020-10-16 DK DK20875989.4T patent/DK4045039T3/da active
- 2020-10-16 KR KR1020227015040A patent/KR20220102669A/ko active Pending
- 2020-10-16 TW TW111127993A patent/TWI802477B/zh active
- 2020-10-16 CA CA3154269A patent/CA3154269A1/en active Pending
- 2020-10-16 UA UAA202201185A patent/UA130059C2/uk unknown
- 2020-10-16 EP EP20875989.4A patent/EP4045039B1/en active Active
- 2020-10-16 FI FIEP20875989.4T patent/FI4045039T3/fi active
- 2020-10-16 LT LTEPPCT/US2020/055986T patent/LT4045039T/lt unknown
- 2020-10-16 TW TW113132607A patent/TWI900200B/zh active
- 2020-10-16 PH PH1/2022/550886A patent/PH12022550886A1/en unknown
- 2020-10-16 TW TW109136036A patent/TWI775182B/zh active
- 2020-10-16 ES ES20875989T patent/ES3035561T3/es active Active
- 2020-10-16 IL IL319053A patent/IL319053A/en unknown
- 2020-10-16 US US17/769,003 patent/US20240174632A1/en active Pending
- 2020-10-16 AR ARP200102870A patent/AR120244A1/es unknown
- 2020-10-16 HU HUE20875989A patent/HUE071814T2/hu unknown
- 2020-10-16 TW TW112116098A patent/TWI857592B/zh active
- 2020-10-16 WO PCT/US2020/056001 patent/WO2021076902A1/en not_active Ceased
- 2020-10-16 CN CN202080088450.4A patent/CN115087444B/zh active Active
- 2020-10-16 BR BR112022007284A patent/BR112022007284A2/pt unknown
- 2020-10-16 JP JP2022523102A patent/JP7437495B2/ja active Active
- 2020-10-16 CU CU2022000027A patent/CU20220027A7/es unknown
- 2020-10-16 PY PY202002065718A patent/PY2065718A/es unknown
- 2020-10-16 CR CR20220205A patent/CR20220205A/es unknown
- 2020-10-16 JP JP2022509595A patent/JP7437490B2/ja active Active
- 2020-10-16 UY UY0001038926A patent/UY38926A/es unknown
- 2020-10-16 RS RS20250645A patent/RS66976B1/sr unknown
- 2020-10-16 EP EP25157767.2A patent/EP4559525A3/en active Pending
- 2020-10-16 PL PL20875989.4T patent/PL4045039T3/pl unknown
- 2020-10-16 PT PT208759894T patent/PT4045039T/pt unknown
-
2021
- 2021-07-16 US US17/378,282 patent/US11370773B1/en active Active
- 2021-10-15 EP EP21881178.4A patent/EP4228634A4/en active Pending
- 2021-10-15 TW TW113110859A patent/TWI888065B/zh active
- 2021-10-15 CN CN202180083775.8A patent/CN116783161B/zh active Active
- 2021-10-15 JP JP2021576053A patent/JP7209116B2/ja active Active
- 2021-10-15 KR KR1020237015039A patent/KR20230088376A/ko active Pending
- 2021-10-15 AU AU2021361031A patent/AU2021361031A1/en active Pending
- 2021-10-15 TW TW110138309A patent/TWI791304B/zh active
- 2021-10-15 TW TW111149835A patent/TWI840047B/zh active
- 2021-10-15 WO PCT/US2021/055196 patent/WO2022081983A1/en not_active Ceased
-
2022
- 2022-04-05 ZA ZA2022/03872A patent/ZA202203872B/en unknown
- 2022-04-13 DO DO2022000081A patent/DOP2022000081A/es unknown
- 2022-04-14 CL CL2022000959A patent/CL2022000959A1/es unknown
- 2022-04-14 IL IL292296A patent/IL292296B2/en unknown
- 2022-05-02 CO CONC2022/0005759A patent/CO2022005759A2/es unknown
- 2022-05-16 EC ECSENADI202238978A patent/ECSP22038978A/es unknown
-
2023
- 2023-01-06 JP JP2023000761A patent/JP7500785B2/ja active Active
- 2023-03-30 ZA ZA2023/03992A patent/ZA202303992B/en unknown
-
2024
- 2024-02-09 JP JP2024018765A patent/JP7717202B2/ja active Active
- 2024-02-09 JP JP2024018866A patent/JP7702004B2/ja active Active
- 2024-06-05 JP JP2024091304A patent/JP2024116230A/ja active Pending
-
2025
- 2025-02-19 DO DO2025000034A patent/DOP2025000034A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4045039T3 (pl) | Hamowanie ludzkiej integryny alfa-4beta-7 | |
| DK3810581T3 (da) | Krystalmodifikationer af odevixibat | |
| DK3720442T3 (da) | Inhibering af mutant idh-1 | |
| DK3749181T3 (da) | Detektering af vævsbeskadigelse | |
| IL286218A (en) | Solid state forms of ripretinib | |
| IL277778B (en) | Bcl6 inhibitors | |
| DK4331584T3 (da) | Terapeutiske anvendelser af deutererede derivater af lanifibranor | |
| DK3773558T3 (da) | Kombinationsbehandling af artritisk sygdom | |
| DK3607068T3 (da) | RNA-interferensmedieret inhibering af TMPRSS6 | |
| DK3807260T3 (da) | Oprensning af nikotin | |
| DK3927899T3 (da) | Nedvibrering af funderinger | |
| DK3678644T3 (da) | Formuleringer af copanlisib | |
| DK3743064T3 (da) | Behandling af proteinuri | |
| IL285765A (en) | Therapeutic uses of dulaglutide | |
| DK3630725T3 (da) | Krystallinsk form af n-butyldeoxygalactonojirimycin | |
| DK3833378T3 (da) | Behandling af vorter | |
| IL285119A (en) | Use of spiropidion | |
| DK3532072T3 (da) | Behandling af glaukom | |
| DK3746279T3 (da) | Sammenkobling af formdele | |
| DK3781172T3 (da) | Behandling af lungebetændelse | |
| DK3638370T3 (da) | Behandling af migræne med acetyl-leucin | |
| EP3962486A4 (en) | ESCAPEMENT OF USP36 | |
| IL281409A (en) | Musk inhibition | |
| EP3965749A4 (en) | ESCAPEMENT OF USP19 | |
| DK3955933T3 (da) | Behandling af migræne |